Literature DB >> 18231640

A pathologic link between Wilms tumor suppressor gene, WT1, and IFI16.

Marianne K-H Kim1, Jacqueline M Mason, Chi-Ming Li, Windy Berkofsky-Fessler, Le Jiang, Divaker Choubey, Paul E Grundy, Benjamin Tycko, Jonathan D Licht.   

Abstract

The Wilms tumor gene (WT1) is mutated or deleted in patients with heredofamilial syndromes associated with the development of Wilms tumors, but is infrequently mutated in sporadic Wilms tumors. By comparing the microarray profiles of syndromic versus sporadic Wilms tumors and WT1-inducible Saos-2 osteosarcoma cells, we identified interferon-inducible protein 16 (IFI16), a transcriptional modulator, as a differentially expressed gene and a candidate WT1 target gene. WT1 induction in Saos-2 osteosarcoma cells led to strong induction of IFI16 expression and its promoter activity was responsive to the WT1 protein. Immunohistochemical analysis showed that IFI16 and WT1 colocalized in WT1-replete Wilms tumors, but not in normal human midgestation fetal kidneys, suggesting that the ability of WT1 to regulate IFI16 in tumors represented an aberrant pathologic relationship. In addition, endogenous IFI16 and WT1 interacted in vivo in two Wilms tumor cell lines. Furthermore, IFI16 augmented the transcriptional activity of WT1 on both synthetic and physiological promoters. Strikingly, short hairpin RNA (shRNA)-mediated knockdown of either IFI16 or WT1 led to decreased growth of Wilms tumor cells. These data suggest that IFI16 and WT1, in certain cellular context including sporadic Wilms tumors, may support cell survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18231640      PMCID: PMC2213901          DOI: 10.1593/neo.07869

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  27 in total

1.  E-cadherin is a WT1 target gene.

Authors:  S Hosono; I Gross; M A English; K M Hajra; E R Fearon; J D Licht
Journal:  J Biol Chem       Date:  2000-04-14       Impact factor: 5.157

2.  Tumor-associated WT1 missense mutants indicate that transcriptional activation by WT1 is critical for growth control.

Authors:  M A English; J D Licht
Journal:  J Biol Chem       Date:  1999-05-07       Impact factor: 5.157

3.  [Inhibitory effect of WT1 gene isoform transfection on proliferation of leukemia cell line NB4].

Authors:  Hui-Ling Shen; Zi-Xing Chen; Wei Wang; Jian-Nong Cen; Shao-Yan Hu; Ye Zhao
Journal:  Ai Zheng       Date:  2006-02

4.  WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin.

Authors:  R E Palmer; A Kotsianti; B Cadman; T Boyd; W Gerald; D A Haber
Journal:  Curr Biol       Date:  2001-11-13       Impact factor: 10.834

5.  Wilms' tumor 1 and signal transducers and activators of transcription 3 synergistically promote cell proliferation: a possible mechanism in sporadic Wilms' tumor.

Authors:  Yu Rong; Long Cheng; Hongxiu Ning; Jizhen Zou; Yuanjiang Zhang; Fang Xu; Li Liu; Zhijie Chang; Xin-Yuan Fu
Journal:  Cancer Res       Date:  2006-08-15       Impact factor: 12.701

6.  The Wilms tumor suppressor WT1 encodes a transcriptional activator of amphiregulin.

Authors:  S B Lee; K Huang; R Palmer; V B Truong; D Herzlinger; K A Kolquist; J Wong; C Paulding; S K Yoon; W Gerald; J D Oliner; D A Haber
Journal:  Cell       Date:  1999-09-03       Impact factor: 41.582

7.  WT1 induces apoptosis through transcriptional regulation of the proapoptotic Bcl-2 family member Bak.

Authors:  Debra J Morrison; Milton A English; Jonathan D Licht
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

8.  CITED1 expression in Wilms' tumor and embryonic kidney.

Authors:  Harold N Lovvorn; Jenifer Westrup; Shaun Opperman; Scott Boyle; Genbin Shi; James Anderson; Elizabeth J Perlman; Alan O Perantoni; Marcia Wills; Mark de Caestecker
Journal:  Neoplasia       Date:  2007-07       Impact factor: 5.715

9.  IFI16 is an essential mediator of growth inhibition, but not differentiation, induced by the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells.

Authors:  Eun-Joo Kim; Jong-In Park; Barry D Nelkin
Journal:  J Biol Chem       Date:  2004-11-30       Impact factor: 5.157

Review 10.  A tumor suppressor and oncogene: the WT1 story.

Authors:  L Yang; Y Han; F Suarez Saiz; F Saurez Saiz; M D Minden
Journal:  Leukemia       Date:  2007-03-15       Impact factor: 11.528

View more
  11 in total

1.  An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1.

Authors:  Marianne K-H Kim; Thomas J McGarry; Pilib O Broin; Jared M Flatow; Aaron A-J Golden; Jonathan D Licht
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-22       Impact factor: 11.205

2.  MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC.

Authors:  D-J Min; T Ezponda; M K Kim; C M Will; E Martinez-Garcia; R Popovic; V Basrur; K S Elenitoba-Johnson; J D Licht
Journal:  Leukemia       Date:  2012-09-13       Impact factor: 11.528

3.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

4.  Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition.

Authors:  Aleksandra Bielen; Gary Box; Lara Perryman; Lynn Bjerke; Sergey Popov; Yann Jamin; Alexa Jury; Melanie Valenti; Alexis de Haven Brandon; Vanessa Martins; Vincent Romanet; Sebastien Jeay; Florence I Raynaud; Francesco Hofmann; Simon P Robinson; Suzanne A Eccles; Chris Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-23       Impact factor: 11.205

5.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

6.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

7.  WT1 induction of mitogen-activated protein kinase phosphatase 3 represents a novel mechanism of growth suppression.

Authors:  Debra J Morrison; Marianne K H Kim; Windy Berkofsky-Fessler; Jonathan D Licht
Journal:  Mol Cancer Res       Date:  2008-07       Impact factor: 5.852

Review 8.  Mechanisms of transcriptional regulation by WT1 (Wilms' tumour 1).

Authors:  Eneda Toska; Stefan G E Roberts
Journal:  Biochem J       Date:  2014-07-01       Impact factor: 3.857

9.  MYCN gene polymorphisms and Wilms tumor susceptibility in Chinese children.

Authors:  Xiaokai Huang; Jie Zhao; Jinhong Zhu; Shanshan Chen; Wen Fu; Xiaoqian Tian; Susu Lou; Jichen Ruan; Jing He; Haixia Zhou
Journal:  J Clin Lab Anal       Date:  2019-07-25       Impact factor: 2.352

10.  DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia.

Authors:  Raajit Rampal; Altuna Alkalin; Jozef Madzo; Aparna Vasanthakumar; Elodie Pronier; Jay Patel; Yushan Li; Jihae Ahn; Omar Abdel-Wahab; Alan Shih; Chao Lu; Patrick S Ward; Jennifer J Tsai; Todd Hricik; Valeria Tosello; Jacob E Tallman; Xinyang Zhao; Danette Daniels; Qing Dai; Luisa Ciminio; Iannis Aifantis; Chuan He; Francois Fuks; Martin S Tallman; Adolfo Ferrando; Stephen Nimer; Elisabeth Paietta; Craig B Thompson; Jonathan D Licht; Christopher E Mason; Lucy A Godley; Ari Melnick; Maria E Figueroa; Ross L Levine
Journal:  Cell Rep       Date:  2014-12-04       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.